Psyence Group Provides Corporate Update Following Successful Spac Spin Out of Therapeutic Division
TORONTO, March 11, 2024 (GLOBE NEWSWIRE) — Further to the announcement by Psyence Group Inc (“Psyence Group” or the “Company“) (CSE:PSYG) of the closing (the “Closing”) of the business combination of its subsidiary, Psyence Biomedical Ltd (“PBM“) (NASDAQ:PBM) with Newcourt Acquisition Corp (“Newcourt“), a special purpose acquisition company, (the “Business Combination” or “Spin–Out“) and the subsequent listing of PBM on the NASDAQ stock exchange with the trading symbol “PBM”, Psyence Group provides a corporate update.
Related news for (PSYGF)
- Psyence Group’s NASDAQ-Listed Associate, Psyence Biomedical, Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial
- Psyence Group’s NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
- Psyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical Business
- Psyence Group’s NASDAQ Listed Associate, Psyence Biomedical, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study